It’s not the people. It’s the product. Very little demand in a VEGF crowded space.
hello there , Alimera had an negotiation last summer with Alergan , they wont buy it.
because in europa are the qualityproblems are rise , so much of the physician won´t the risk of an
emergency vitrectomy . today they stuck in an investigation of sexual assault and bullying of a supervisor. (#metoo) ; so its a happy place there
HR lady is cut throat agreed Outdated policies and little empathy to employees mgmt here in my area is great and hiring new people to right the ship there is a different component to this product vs other in this retinal space MH is changing the approach and many including myself is glad as we have been on the downhill for years as someone who has been here a while i have watched many changes and it seems this year what is needed is finally happening we have been waiting far too long to make changes and am glad things are turning around EU is changing too and finally picking up where it is needed and much needed data is out for patients to see this good product will get to find patients now
As of December 31, 2017 Alimera Sciences has a debt of $399.1 Million. Gross profit increased by $500,000 or 2% in 2017. As of December 31, 2017 Alimera Sciences had 24.1 Million in cash or cash equivalents.
My math isn’t so good so I was wondering if someone can help me figure this out. When you make a profit of $500,000 per year...how long does it take to pay down $399.1 Million?
